fda tirzepatide shortage resolved date Resolves Shortage: Impact on Supply Chain FDA Update: Current Guidelines for

In young adults, the number of those dispensed liraglutide, dulaglutide or exenatide was greatest in 2020 and 2021, whereas the number dispensed injectable semaglutide for type 2 diabetes was greatest in 2022 and 2023

Each of these medications is backed by clinical data, supporting their usage in weight management rather than in diabetes treatment, which Mounjaro targets

secretory phenotype (SASP) Interest in how modulation of senescent-cell burden affects tissue in research settings

When Switching Makes Sense and When It Doesnt Switching to tirzepatide may be a good option if: Weight loss has stalled despite consistency Side effects are limiting progress Appetite control remains a challenge Staying on semaglutide may make sense if: Weight loss is steady Side effects are minimal The current dose is working well The right choice depends on how your body is responding, not on comparisons alone

Key insight: Accurate, patent-by-patent assessment is essential when evaluating timelines for generic availability and potential affordability